Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial Fibrillation


Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School, Boston, MA

After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at MIT while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master of Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. Dr. Bhatt completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. Most recently he received the AHA’s Distinguished Scientist Award in 2019 in addition to numerous other honors. Dr. Bhatt has been listed in Best Doctors in America from 2005 to 2020.

Dr. Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored over 1500 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2019. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and co- PI of STAMPEDE. Additionally, Dr. Bhatt serves as chair for REDUCE- IT and SCORED. In 2018, REDUCE-IT was listed and named the top cardiology trial by NEJM. In 2014, he was listed in the AHA/ASA top ten advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3).He serves as Senior Associate Editor for News and Clinical Trials for, Editor of the peer-reviewed Journal of Invasive Cardiology, as well as Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and Atherothrombosis in Clinical Practice published by Oxford University Press. He also serves as Editor-in-Chief of the Harvard Heart Letter for patients.

Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation
Cardiovascular Division, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School Boston, MA
Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation

Christopher P. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital. He currently serves as Education Director in the Cardiovascular Innovation group. For 25 years, Dr. Cannon served as an investigator in the TIMI Study Group. He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, and RE-DUAL PCI trials, and is a lead investigator for VERTIS CV. In his role at Cardiovascular Innovation, he is helping to implement the quality improvement program ‘Remote Health’ for lipids and hypertension.

Associate Professor, Department of Family and Community Medicine
Lewis Katz School of Medicine at Temple University, Philadelphia, PA

Margot Savoy, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL is Associate Professor for the Department of Family & Community Medicine at the Lewis Katz School of Medicine at Temple University and Temple University Hospital, and Chief Quality Officer for the Temple Faculty Practice Plan. She is an attending physician at Temple University Hospital (Philadelphia, PA) and Christiana Care Health System (Wilmington, DE). Dr. Savoy graduated from the University of Maryland School of Medicine in 2002, completed Family Medicine Residency Program at the Crozer-Keystone Family Medicine Residency Program (Springfield, PA) in 2005, and graduated from the University of North Carolina Chapel Hill Gillings School of Global Public Health in 2008 with a Master’s degree in Public Health in Public Health Leadership with a focus on Public Health Practice. She is certified by the American Board of Family Medicine, the Certifying Commission in Medical Management, and is a Fellow of the Advisory Board Company.

Statement of Need

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by increased screening and guideline-directed anticoagulation treatment. Unfortunately, despite the fact that both opportunistic and systematic screening have been shown to be effective in detecting NVAF, clinicians often lack knowledge of the available tools and strategies for implementing it, particularly in primary care settings.

This CME Outfitters Live and OnDemand webcast will feature expert faculty addressing the impact of undiagnosed NVAF, the benefit and use of screening tools for early detection, best practices for optimizing screening, implementing oral anticoagulant therapy for stroke prevention, and the use of digital health technologies, with a goal of fostering collaborative care and optimizing patient outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Implement opportunistic and systematic screening in primary care settings to identify patients with NVAF who might benefit from anticoagulant therapy.
  • Integrate current guidelines into the management of patients with NVAF.
  • Incorporate the latest resources and strategies to facilitate collaborative care and optimize patient outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain how to identify patients with NVAF in the primary care setting who might benefit from anticoagulant therapy.
  • Summarize current guidelines on the management of patients with NVAF.
  • Discuss the latest resources and strategies for collaborative care and optimized patient outcomes.

Financial Support

Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Target Audience

Primary care physicians, cardiologists, nurse practitioners, PAs, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bhatt reports he is a consultant for Abbott; Afimmune; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals: Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.

Dr. Cannon reports that he receives research grants from Amgen Inc.; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He is a consultant for Aegerion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals ,Inc.; Amarin Corporation; Amgen Inc.; Applied Therapeutics; Ascendia Pharmaceuticals; Boehringer-Inghelheim; Bristol-Myers Squibb Company; Corvidia; Eli Lilly and Company; HLS Therapeutics Inc.; Innocent Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc.; and Sanofi-Aventis.

Dr. Savoy has no disclosures to report.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Rachel Speer, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-121-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).




Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial Fibrillation
Event Date: 10/07/2020